Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Everolmus · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Everolimus | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Everolmus | DRUG | - |
Inclusion criteria: * Patients must have histopathologically confirmed diagnosis of non-Hodgkin's lymphoma * Patients must have disease that is either relapsed or refractory after at least one prior treatment regimen and must not be eligible for any standard treatments * Patients must not have rece...
Everolmus is an investigational small molecule being studied for the treatment of relapsed or refractory Non-Hodgkin's Lymphoma. It is being developed by Novartis AG and is currently in Phase 1 clinical development. The drug has been evaluated in a completed Phase 1 dose escalation study in patients with this condition.
Everolmus is being developed by Novartis AG, a pharmaceutical company traded on the stock exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development for the treatment of Non-Hodgkin's Lymphoma, a type of cancer affecting the lymphatic system.
Everolmus is in Phase 1 clinical development. It has completed a Phase 1 dose escalation study in patients with relapsed or refractory Non-Hodgkin's Lymphoma. The drug is investigational and has not yet been approved by regulatory authorities for any use.
Everolmus has been studied in one clinical trial with the identifier NCT00622258, titled "A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma." This trial was completed and enrolled 13 participants in Japan, with a minimum age of 20 years.
Yes, Everolmus is also known as RAD001. The clinical trial NCT00622258, which studied Everolmus in Non-Hodgkin's Lymphoma, refers to the drug as RAD001. This alternative name is used in the context of the Phase 1 dose escalation study conducted in Japan.